The Boston-based company is developing a multi-modal approach to stop or slow the progression of neurodegenerative diseases, with a lead candidate, ALZT-OP1, currently in a Phase 3 trial for early Alzheimer’s disease. AZTherapies is also advancing candidates for the treatment of post-ischemic stroke cognitive impairment, ALS, and other indications. The company's innovative approach recognizes neuroinflammation as a root cause of neurodegeneration and leverages the ability of cromolyn, a small molecule, to shift the brain’s innate immune cells from a pro-inflammatory to neuroprotective state.